Skip to main content

Advertisement

ADVERTISEMENT

Volume 24 - Issue 6 - June 2012

05/29/2012

Nicolas W. Shammas, MD, MS1, Gail A. Shammas, BS, RN1, Jon Lemke, PhD2, Sue Miller, MS2, Susan Meriner, MD1

Nicolas W. Shammas, MD, MS1, Gail A. ...
Abstract: Background. Gender-related differences in long-term outcomes of patients receiving the Endeavor zotarolimus-eluting stent (ZES) (Medtronic) have not been well defined. In this study, we evaluate the differences between men (M) and...
Abstract: Background. Gender-related differences in long-term outcomes of patients receiving the Endeavor zotarolimus-eluting stent (ZES) (Medtronic) have not been well defined. In this study, we evaluate the differences between men (M) and...
Abstract: Background....
05/29/2012
Journal of Invasive Cardiology

Feature

Original Contribution
05/29/2012

Gennaro Galasso, MD, Raffaele Piccolo, MD, Salvatore Cassese, MD, Giovanni Esposito, MD, Plinio Cirillo, MD, Dario Leosco, MD, Antonio Rapacciuolo, MD, Domenico Sirico, MD, Chiara De Biase, MD, Tullio Niglio, MD, Federico Piscione, MD

Gennaro Galasso, MD, Raffaele Piccolo...
Abstract: Background. To evaluate the safety and efficacy of unrestricted Endeavor Resolute zotarolimus-eluting stent (ZES) use. Furthermore, we sought to evaluate clinical outcomes associated with on- and off-label use of Resolute ZES....
Abstract: Background. To evaluate the safety and efficacy of unrestricted Endeavor Resolute zotarolimus-eluting stent (ZES) use. Furthermore, we sought to evaluate clinical outcomes associated with on- and off-label use of Resolute ZES....
Abstract: Background. To...
05/29/2012
Journal of Invasive Cardiology

Advertisement

Advertisement

Advertisement